Skip to Content

Foresight Biotherapeutics Announces Presentation at the 2010 Association for Research in Vision and Ophthalmology

NEW YORK--(BUSINESS WIRE)--Apr 22, 2010 - Foresight Biotherapeutics, Inc. today announced data from a pre-clinical study will be presented at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) being held in Ft. Lauderdale, Florida. The study was designed to assess the safety and efficacy of the topical administration of FST-100 in a widely accepted rabbit model of adenoviral conjunctivitis. FST-100 is the company's lead product for the treatment of adenoviral conjunctivitis. The results demonstrated a statistically significant effect in both clinical cure and adenoviral eradication. The work was conducted at the Louisiana State University (LSU) Health Sciences Center, LSU Eye Center in New Orleans, Louisiana by Professor James M. Hill and colleagues. Detailed data are being presented at a poster discussion session on Wednesday, May 5th at 8:30am-10:15am.

The study supports the potential for our product in the lead indication of adenoviral conjunctivitis. Adenoviral conjunctivitis or “pink eye” is one of the most common eye infections worldwide. It is highly contagious and is a frequent cause of epidemics. There is currently no drug approved for the treatment of adenoviral conjunctivitis.

About Foresight Biotherapeutics, Inc.

Foresight Biotherapeutics is a drug development company focused on diseases of the eye and ear. The company's website is:

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Foresight relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Foresight's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Foresight and/or its partners to develop, manufacture and commercialize, Foresight's ability to fund such efforts with or without partners, and other risks.


Contact: Foresight Biotherapeutics
Investor Relations, 646-747-9100


Posted: April 2010